



C-RAD and RaySearch sign collaboration agreement

C-RAD AB (publ) and RaySearch Laboratories AB (publ) are pleased to announce a collaboration agreement, aiming at jointly developing innovative solutions and products to enhance the quality of radiation therapy.

The focus of the collaboration is to investigate how the C-RAD surface scanning technologies can be utilized during treatment planning in RaySearch's treatment planning system RayStation. Today, the surfaces from the C-RAD surface guided radiation therapy system, Catalyst+, are used during imaging and treatment. Making the Catalyst+ surfaces available in RayStation has many potential applications. One such application is to extend a cone beam CT image that has a limited field-of-view by using information from the surface scanning. This will lead to more complete representation of the patient's anatomy, which in turn results in a more dependable basis for clinical decisions. As a first outcome of the announced collaboration, the above-described application will be demonstrated at the ongoing trade show ESTRO, with a continuation to explore other applications of the companies' respective products.

Cecilia de Leeuw, CEO and President, C-RAD, says: "We are thrilled about the collaboration with RaySearch, where we will enhance and find new innovative solutions in our common fight against cancer.

Johan Löf, founder and CEO, RaySearch, says: "I look forward to collaborating with C-RAD, which is also located close to us in Sweden. The additional information about the patient's anatomy provided by surface scanning from Catalyst has the potential to greatly improve different steps in the radiation therapy treatment planning process in RayStation."

About C-RAD

C-RAD develops surface-guided imaging solutions for radiation therapy to allow highly accurate dose delivery to the tumor, and at the same time, to protect healthy tissue from unwanted exposure. Using high-speed 3D cameras combined with augmented reality, C-RAD supports the initial patient setup process and monitors the patient's motion during treatment to ensure high confidence, an efficient workflow, and improved accuracy. C-RAD monitors the patient's motion without the use of tattoos or additional imaging dose, to deliver the highest level of patient safety and comfort. C-RAD AB is listed on NASDAQ Stockholm. For more information, please visit [c-rad.com](https://www.c-rad.com).

About RaySearch

RaySearch Laboratories AB (publ) is a medical technology company that develops innovative software solutions for improved cancer treatment. RaySearch markets the RayStation®* treatment planning system (TPS) and the oncology information system (OIS) RayCare®*. The most recent additions to the RaySearch product line are RayIntelligence® and RayCommand®*. RayIntelligence is an oncology analytics system (OAS) which enables cancer clinics to collect, structure and analyze data. RayCommand, a treatment control system (TCS), is designed to link the treatment machine and the treatment planning and oncology information systems.

Press Release
04 May 2024 13:00:00 CEST



RaySearch's software has been sold to over 1,000 clinics in 43 countries. The company was founded in 2000 as a spin-off from the Karolinska Institute in Stockholm and the share has been listed on Nasdaq Stockholm since 2003. More information is available at raysearchlabs.com.

** Subject to regulatory clearance in some markets.*

For further information:

Cecilia de Leeuw, CEO, +46 (0)795 85 66 77, investors@c-rad.com

Attachments

[C-RAD and RaySearch sign collaboration agreement](#)